NARSAD Grants Support Discovery of New Potential Class of Rapid-Acting Antidepressant

Printer-friendly versionPrinter-friendly version
Stephanie Dulawa, Ph.D. - Brain and behavior research expert on depression
Stephanie Dulawa, Ph.D.

For several years now, mental health researchers have been studying new rapid-acting antidepressants such as ketamine and scopolamine to treat severe depression. The benefit of these medications is that they treat depression symptoms in hours as opposed to weeks, as is typical for most antidepressants currently on the market.

"One of the biggest problems in the treatment of depression today is a delay in onset of therapeutic effects. There has been a great need to discover faster-acting drugs," said, Stephanie Dulawa, Ph.D., Associate Professor of Psychiatry and Behavioral Neuroscience at the University of Chicago, who used her second NARSAD Young Investigator Grant for this study. In a paper published Oct. 29th in Molecular Psychiatry, Dr. Dulawa and her team report on a new potential class of fast-acting antidepressants that appear to be more suitable for human use with fewer side effects.

In seeking a new class of fast-acting therapeutics, Dr. Dulawa and team tested biological pathways previously shown to generate antidepressant effects that had never been studied for rate of onset of symptom alleviation. They looked at different subtypes of serotonin receptors, proteins that are binding partners for serotonin, a neurotransmitter that has been shown to regulate mood, memory and appetite. Of these subtypes, serotonin 2C receptors stood out. 

When these 2C receptors were selectively blocked in mice, a reduction in depression-like behaviors in five days was observed compared to a minimum of two weeks for a control antidepressant medication.The researchers believe that this new biological mechanism could offer a much safer alternative to ketamine and scopolamine. The team is now investigating methods of testing the blocking of these 2C receptors that will be suitable for clinical trials.

Read the press release from the University of Chicago.

Article comments

So we are still working with animal models? Is there any progress toward understanding the biological basis of this thing called depression that everyone is trying to treat?

How long has it been since there has been a real breakthrough in the treatment of depression? One that provides lasting relief for a major portion of the affected population?

Wouldn't reliable bio-markers provide a better target to aim at?

I am very interested in the research being done on fast-acting antidepressants and would like to know which institutions are currently offering these drugs to patients. If these drugs are currently in clinical trials, is the Mayo Clinic one of the places that is holding these trials? I can be reached at: judyphllps440@gmail.com
Thank you.

Add new comment

comments

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Please note that researchers cannot give specific recommendations or advice about treatment; diagnosis and treatment are complex and highly individualized processes that require comprehensive face-to- face assessment. Please visit our "Ask an Expert" section to see a list of Q & A with NARSAD Grantees.
By submitting this form, you accept the Mollom privacy policy.